var title_f17_28_17856="Echogenic fetal intracardiac focus";
var content_f17_28_17856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echogenic fetal intracardiac focus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sonographic criteria for echogenic intracardiac foci is brightness equivalent to that of bone. Echogenic intracardiac foci usually occur as a single focus in the left ventricle, but multiple foci, biventricular foci, or a right ventricular location can also occur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beryl R Benacerraf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17856=[""].join("\n");
var outline_f17_28_17856=null;
var title_f17_28_17857="Adie's pupil";
var content_f17_28_17857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left Adie's pupil",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The left pupil is dilated and poorly reactive to light. B) At near, the left pupil constricts slowly. C) After instillation of dilute pilocarpine (0.1 percent), the left pupil constricts while the right pupil does not constrict.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17857=[""].join("\n");
var outline_f17_28_17857=null;
var title_f17_28_17858="Lunge PI";
var content_f17_28_17858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lunge",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stand with the feet together. Step the right foot approximately 36 inches in front of the body. The right knee should be over the right ankle. Hold for 5 seconds. Step the right foot back so that the feet are together. Rest as needed. Repeat with the left leg. Repeat 10 to 15 times (one set). Perform a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17858=[""].join("\n");
var outline_f17_28_17858=null;
var title_f17_28_17859="Double decidual sign";
var content_f17_28_17859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Double decidual sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal image demonstrating the double decidual sac sign in the endometrium.",
"    <div class=\"footnotes\">",
"     G: gestational sac.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17859=[""].join("\n");
var outline_f17_28_17859=null;
var title_f17_28_17860="Superficial spreading melanoma 3";
var content_f17_28_17860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lesion is asymmetric, presents irregular borders and irregular distribution of the pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17860=[""].join("\n");
var outline_f17_28_17860=null;
var title_f17_28_17861="Valgus injury to distal femur in the adolescent";
var content_f17_28_17861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Valgus injury to the distal femur in the adolescent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Valgus and torsional stress across the knee may cause a physeal separation.",
"    <br/>",
"    (B) In the skeletally immature athlete the medial collateral ligament remains intact and a Salter-Harris II (pictured) or III fracture occurs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Price CT, Herrera-Soto J. Extra-articular injuries of the knee. In: Rockwood and Wilkins' Fractures in Children, 7th edition, Beaty JH, Kasser JR. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17861=[""].join("\n");
var outline_f17_28_17861=null;
var title_f17_28_17862="ECG SA nodal reentrant tachycardia";
var content_f17_28_17862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1041px;\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing sinoatrial (SA) nodal reentrant tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 85px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing SA nodal reentrant tachycardia. The first three beats are normal sinus beats at a rate of about 107 beats/min; the fourth beat is an atrial premature beat that is followed by a return to sinus rhythm. The eighth beat (arrow) represents the sudden onset of SA nodal reentrant tachycardia at a rate of about 145 beats/min. Since the P waves are similar to the sinus beats, the diagnosis is suggested only by the abrupt onset of the tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17862=[""].join("\n");
var outline_f17_28_17862=null;
var title_f17_28_17863="3D SHAX view of nonclassic MVP";
var content_f17_28_17863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1166px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83603/3D_SHAX_nonclass_MVP_video.mp4?title=3D+SHAX+view+of+nonclassic+MVP\" style=\"width:512px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Three-dimensional short-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with fibroelastic deficiency with flail P2 scallop. Note focal involvement of the middle posterior scallop.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1176px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83605/3D_SHAX_classic_MVP_video.mp4?title=3D+SHAX+view+of+nonclassic+MVP\" style=\"width:512px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Three-dimensional short-axis echocardiographic view of classic mitral valve prolapse with bileaflet prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with classic Barlow's disease. Note diffusely thickened anterior and posterior leaflets, with massive prolapse mostly of the P2-P3 scallops.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17863=[""].join("\n");
var outline_f17_28_17863=null;
var title_f17_28_17864="Diclofenac and misoprostol: Drug information";
var content_f17_28_17864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diclofenac and misoprostol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/60/27589?source=see_link\">",
"    see \"Diclofenac and misoprostol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arthrotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Arthrotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;",
"     </li>",
"     <li>",
"      Prostaglandin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoarthritis:",
"     </b>",
"     Oral: Arthotec&reg; 50: 1 tablet 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Arthotec&reg; 50: 1 tablet 3 or 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For both indications, may administer Arthrotec&reg; 50 or Arthrotec&reg; 75 one tablet twice daily if recommended dose is not tolerated; however, these options are less effective in preventing GI ulceration. May adjust dose using individual agents in combination with Arthrotec&reg;. The maximum daily dose of misoprostal is 800 mcg and the maximum single dose of misoprostal is 200 mcg. The maximum daily dose of diclofenac is 150 mg/day (osteoarthritis) or 225 mg/day (rheumatoid arthritis).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F159435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in patients with advanced renal disease. In renal insufficiency, diclofenac should be used with caution due to potential detrimental effects on renal function, and misoprostol dosage reduction may be required if adverse effects occur (misoprostol is renally eliminated).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7729404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May require dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: Diclofenac sodium 50 mg and misoprostol 200 mcg; Diclofenac sodium 75 mg and misoprostol 200 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Arthrotec&reg; 50: Diclofenac sodium 50 mg and misoprostol 200 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Arthrotec&reg; 75: Diclofenac sodium 75 mg and misoprostol 200 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085919.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085919.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9645995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Incidence of diarrhea may be lessened by having patient take dose right after meals and avoiding magnesium containing antacids. Tablets should not be crushed or chewed. Therapy is usually begun on the second or third day of the next normal menstrual period in women of child bearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of osteoarthritis and rheumatoid arthritis in patients at high risk for NSAID-induced gastric and duodenal ulceration",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported with combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Abdominal pain (21%), diarrhea (19%), dyspepsia (14%), nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Flatulence (9%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diclofenac, misoprostol, other prostaglandins, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs (Bhatt, 2008). Concomitant gastroprotective therapy (eg, misoprostol as part of Arthrotec&reg;) should be used for patients at high risk for NSAID-related ulcer complications and who require NSAID therapy when alternative therapy is not possible. An alternative NSAID with lower cardiovascular event risk (as opposed to diclofenac as part of Arthrotec&reg;) should be considered in patients requiring both NSAIDs and low-dose aspirin (Lanza, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Transaminase elevations have been observed with chronic use, generally within in the first 2 months of therapy, but may occur at any time (manufacturer labeling). A recent clinical trial concluded that transaminase elevations occur 4-6 months after initiation of therapy (Laine, 2009). Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur. Significant elevations in transaminases (eg, &gt;3 x ULN) occur before patients become symptomatic. Periodic transaminase monitoring should occur in patients on chronic therapy beginning 4-8 weeks after initiation. Patients should be educated about symptoms of hepatotoxicity. Avoid concurrent hepatotoxins if possible and use the lowest effective dose for the shortest duration. Discontinue therapy if hepatic injury is suspected (persistent or worsening LFT abnormality, clinical signs/symptoms of liver disease, or systemic manifestations of hypersensitivity (eosinophilia, rash).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension. Monitor blood pressure closely with therapy initiation and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Avoid use in patients with hepatic porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Not to be used in women of childbearing potential unless woman is capable of complying with effective contraceptive measures;",
"     </b>",
"     therapy is normally begun on the second or third day of next normal menstrual period. NSAID use late in pregnancy may cause prenatal constriction of the ductus arteriosus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Due to the abortifacient property of this medication, patients must be warned not to give this drug to others.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F159442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used together with voriconazole.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2250668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F159425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not observed with this combination in animal reproduction studies; however, adverse fetal events have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to both diclofenac and misoprostol in human pregnancy.",
"     <b>",
"      [U.S. Boxed Warning]: Not to be used to reduce NSAID-induced ulcers in women of childbearing potential unless woman is capable of complying with effective contraceptive measures.",
"     </b>",
"     Do not use in women of childbearing potential without a negative serum pregnancy test within 2 weeks prior to therapy; therapy is normally begun on the second or third day of next normal menstrual period. Use to prevent NSAID-induced ulcers is contraindicated in pregnant women. Written and verbal warnings concerning the hazards of misoprostol should be provided. Also refer to individual monographs for Diclofenac and Misoprostol for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9645921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Arthrotec Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-200 mg-mcg (90): $365.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75-200 mg-mcg (60): $243.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diclofenac-Misoprostol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-200 mg-mcg (60): $201.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75-200 mg-mcg (60): $201.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7729405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC, liver enzymes (periodically during chronic therapy starting 4-8 weeks after initiation); monitor urine output and BUN/serum creatinine; occult blood loss; adequate diagnostic measures in all cases of undiagnosed abnormal vaginal bleeding",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F159426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arthrotec (AE, BF, BG, BH, BJ, CI, CY, CZ, DK, EE, EG, ET, FI, GB, GH, GM, GN, GR, HK, HN, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, QA, SA, SC, SD, SE, SL, SN, SY, TN, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Arthrotec 50 (AU);",
"     </li>",
"     <li>",
"      Artotec (FR, RU);",
"     </li>",
"     <li>",
"      Artrotec (ES, IT, MX, PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laine L, Goldkind L, Curtis SP, et al, &ldquo;How Common Is Diclofenac-Associated Liver Injury? Analysis Of 17,289 Arthritis Patients In A Long-Term Prospective Clinical Trial,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):356-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/19174782/pubmed\" id=\"19174782\" target=\"_blank\">",
"        19174782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanza FL, Chan FK, Quigley EM, et al, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(3):728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/19240698/pubmed\" id=\"19240698\" target=\"_blank\">",
"        19240698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/28/17864/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8433 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17864=[""].join("\n");
var outline_f17_28_17864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708700\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159429\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159430\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159448\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159433\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159434\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159435\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7729404\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159418\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159406\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874604\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645995\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159420\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159446\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159423\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159410\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159442\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159414\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2250668\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159415\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159425\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159437\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645921\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524490\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7729405\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159426\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159409\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159422\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8433\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8433|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/60/27589?source=related_link\">",
"      Diclofenac and misoprostol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_28_17865="Treatment of cysticercosis";
var content_f17_28_17865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of cysticercosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/28/17865/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17865/contributors\">",
"     A Clinton White, Jr, MD, FACP, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/28/17865/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17865/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/28/17865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17865/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/28/17865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysticercosis is caused by the larval stage (metacestode) of the pork tapeworm Taenia solium. Clinical syndromes related to this parasite are divided into neurocysticercosis (NCC) and extraneural cysticercosis. Neurocysticercosis, in turn, is divided into parenchymal and extraparenchymal forms. The most common presentation of parenchymal NCC is seizures, whereas extraparenchymal NCC typically presents with hydrocephalus. Treatment must be individualized based on the manifestations of disease.",
"   </p>",
"   <p>",
"    The treatment of cysticercosis will be reviewed here. The epidemiology, transmission, prevention, clinical features and diagnosis of cysticercosis and the life cycle of T. solium are discussed in separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15413?source=see_link\">",
"     \"Epidemiology, transmission and prevention of cysticercosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28232?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to patients with clinical manifestations of neurocysticercosis (NCC) should focus on management of symptoms such as seizure control with antiepileptics and treatment of increased intracranial pressure, if present. Subsequently a determination should be made regarding the role of antiparasitic and anti-inflammatory therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antiepileptic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptics should be administered to patients with NCC who present with seizures. Most reports in the literature on management of seizure due to NCC describe use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . Newer therapies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ) are likely to be at least as effective, perhaps better tolerated, although more costly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiepileptic therapy may also be appropriate for patients who do not present with seizures but who are at high risk for seizures. The risk of seizures appears to be highest in the setting of multiple lesions, particularly when the lesions are degenerating and are surrounded by inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Calcified, inactive lesions can also serve as foci for seizures but in an otherwise asymptomatic patient are not generally considered an indication for prophylactic antiepileptic drug therapy.",
"   </p>",
"   <p>",
"    The optimal duration of antiepileptic therapy is uncertain. In general, indefinite therapy may be appropriate in the setting of calcified lesions, especially in those with recurrent seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/7\">",
"     7",
"    </a>",
"    ]. In some cases these patients may taper therapy successfully. Although it is uncertain whether the radiographic resolution of cysts results in seizure remission, most experts favor administering antiepileptic therapy for 6 to 12 months after radiographic resolution of active parasitic infection. If the patient has recurrence of seizures during a trial off of antiepileptic therapy, long-term treatment should be reinstituted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antiparasitic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus on the optimal role of antiparasitic therapy in the setting of cysticercosis is beginning to emerge. Because neurocysticercosis represents a spectrum of manifestations, the use of antiparasitic drugs for different forms of the disease is outlined separately in the following sections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefit of antiparasitic therapy for treatment of neurocysticercosis is hastened resolution of active cysts, decreased risk for seizures, and decreased recurrence of hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the data regarding the role of antiparasitic therapy in improved resolution of cysts or better seizure control are only now emerging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential risk of treatment with antiparasitic therapy is exacerbation of neurologic symptoms due to increased inflammation around the degenerating cyst, particularly in patients with a large number of lesions. The inflammation can be so severe that it can lead to disability or death. For this reason, corticosteroids should be routinely administered together with antiparasitic therapy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Anti-inflammatory therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If a determination has been made that antiparasitic therapy is indicated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    is preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    given its favorable pharmacokinetic profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Albendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [usually 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in two divided doses; taken with food to increase bioavailability]) facilitates the destruction of parenchymal cysticerci. Higher doses have been used in cases of subarachnoid NCC, but there are insufficient data on the safety of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/11\">",
"     11",
"    </a>",
"    ]. Older studies suggest albendazole treatment may facilitate clearance of up to 90 percent of parasites, although more recent randomized controlled trials have noted a more modest effect [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Albendazole does not interact with antiepileptic medications (in contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    ). Coadministration of corticosteroids has no adverse effect on albendazole levels and may even raise serum drug concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients with parenchymal lesions appear to benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    therapy (rather than symptomatic management alone). This was illustrated in a meta-analysis of controlled trials comparing albendazole with placebo in nearly 500 patients with single enhancing lesions and nearly the same number of cystic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Radiographic resolution was noted more frequently among those who received albendazole than those who did not (69 versus 55 percent, respectively for enhancing lesions).",
"   </p>",
"   <p>",
"    The optimal duration of therapy depends on the form of disease. Patients with a single enhancing lesion appear to benefit from a short course of therapy (3 to 7 days). This was illustrated in a study of 122 children with up to three lesions; 7 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    was as effective as 28 days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/17\">",
"     17",
"    </a>",
"    ]. Another study of eight patients with single enhancing lesions demonstrated that there were no persisting viable cysts following 3 days of therapy with albendazole [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with multiple viable parenchymal lesions should receive a longer course of treatment (10 to 14 days); this approach is largely based on expert opinion with limited data. One controlled trial including 120 patients randomized to receive 10 days of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    OR two placebos demonstration a reduction in seizures with generalization by 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/2\">",
"     2",
"    </a>",
"    ]. Six months following albendazole therapy, MRI only demonstrated complete resolution in 38 percent of cases and persistent viable cysts in 41 percent of cases.",
"   </p>",
"   <p>",
"    Patients with subarachnoid disease may benefit from prolonged therapy guided by the response on imaging studies (&ge;28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/19\">",
"     19",
"    </a>",
"    ]. This was illustrated in a series of 33 patients with intracranial hypertension and subarachnoid cysts at least 50 mm in diameter. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    four weeks; 10 patients were subsequently treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    for four weeks. In addition, 17 patients received a second course of albendazole, 3 received a third course, and 1 received a fourth course. After a median of 59 months of follow-up, all 33 patients had improved and the cysts had disappeared or become calcified. Of the 22 patients with a history of seizures, 11 continued to receive antiseizure medications. In general, patients should be observed closely for signs of clinical deterioration during the first week of therapy; this may require hospitalization.",
"   </p>",
"   <p>",
"    Information is emerging on the use of combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    dosed together. The combination is generally safe and may be more effective than albendazole alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. When dosed together, the levels of albendazole sulfoxide (the active metabolite of albendazole) are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/20\">",
"     20",
"    </a>",
"    ]. A randomized trial comparing albendazole with both drugs in 103 children with single enhancing lesions demonstrated a higher rate of resolution and lower rate of calcifications in those on the combination therapy compared to albendazole alone (72 percent versus 52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/21\">",
"     21",
"    </a>",
"    ]. Similar data are emerging for parenchymal cystic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Praziquantel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     Praziquantel",
"    </a>",
"    (50 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses) is an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. Randomized trials comparing praziquantel to albendazole have not demonstrated a difference in efficacy; some of these have been limited by poor quality design [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the efficacy of praziquantel may be reduced by induction of cytochrome P-450 hepatic metabolism by coadministered drugs such as corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, the bioavailability of praziquantel is enhanced by co-administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , grapefruit juice, or fatty or high carbohydrate meals.",
"   </p>",
"   <p>",
"    Single day treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    prior to initiation of antiepileptic drugs and corticosteroids has been attempted, but is likely less effective than standard course regimens. In the setting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    failure, prolonged praziquantel has been used. In such cases, doses of 50 to 60",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    co-administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    may be optimal.",
"   </p>",
"   <p>",
"    The approach to treatment of tapeworm infection with T. solium is discussed in detail separately (\"Intestinal tapeworms\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anti-inflammatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids should be administered to patients with parenchymal neurocysticercosis receiving treatment with antiparasitic therapy, to reduce inflammation associated with the dying organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Four randomized controlled trials of patients with single enhancing lesions in India have examined the effects of corticosteroids on seizure recurrence and radiographic resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. In all of these studies, patients who received steroids had better seizure control and faster radiologic resolution than those who did not receive steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No controlled data are available on the use of corticosteroids in other forms of neurocysticercosis, although corticosteroids are appear to play a useful role in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steroids are the mainstay of therapy in patients with cysticercal encephalitis (diffuse cerebral edema due to numerous inflamed cysticerci) given their capacity to reduce cerebral edema [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,10\">",
"       8,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Steroids have been used to reduce symptoms in subarachnoid cysticercosis; prolonged tapers have been used in the setting of recurrent symptoms. In cases requiring extended courses of steroids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      may be a useful steroid sparing agent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Doses used are typically 1",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or 0.1",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for 5 to 10 days followed by a rapid taper. Higher doses may be more effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prior to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following considerations should be made prior to the initiation of therapy with antiparasitic medications and corticosteroids:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most regions and groups at risk for neurocysticercosis are also at risk for tuberculosis. Thus, they should be screened for latent tuberculosis prior to initiation of corticosteroids. This can be accomplished using a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      or interferon gamma release assay. If either test is positive, individuals receiving steroids for longer than a few weeks should receive treatment for latent tuberculosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"       \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since many patients with cysticercosis also have risk factors for strongyloidiasis, which can disseminate during treatment with corticosteroids, it may be wise to screen for strongyloidiasis prior to embarking on steroid therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"       \"Strongyloidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An ophthalmologic examination should be performed to rule out ocular cysticercosis. A direct fundoscopic examination is usually adequate for visualization of cysticerci.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention is generally required in the setting of symptomatic hydrocephalus due to NCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In the absence of acute symptoms, cysticerci in the ventricles may be removed endoscopically, which may be associated with fewer long-term sequelae than open resection or shunting accompanied by medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with altered mental status or impending herniation generally require emergent CSF diversion via either a ventriculostomy or placement of a ventriculo-peritoneal shunt. Shunt failure is common, and placement should be accompanied by anti-parasitic therapy and corticosteroids (although it is unproven whether these decrease the risk of shunt blockage and malfunction) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with subarachnoid cysticercosis and arachnoiditis frequently develop communicating hydrocephalus; in such cases management requires placement of a ventriculoperitoneal shunt together with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,31,32\">",
"     8,31,32",
"    </a>",
"    ]. Some patients may also benefit from endoscopic debulking (which is best accomplished using a flexible endoscope via a third ventriculostomy).",
"   </p>",
"   <p>",
"    Open resection is rarely required in NCC, but may be warranted in certain circumstances such as giant cysticerci with life-threatening mass effect, cysticerci localized to the fourth ventricle, cysticerci adjacent to vascular structures, and cysticerci at sites inaccessible by flexible endoscopy (such as ocular or spinal NCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PARENCHYMAL NCC",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Single lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single enhancing lesion accompanied by seizure is a common clinical presentation of NCC. The seizures are controllable with antiepileptic medication alone and the prognosis is favorable with symptomatic treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controlled trials have demonstrated that patients treated with antiparasitic drugs have slightly shorter duration of seizure risk and time to radiologic resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/15,34-36\">",
"     15,34-36",
"    </a>",
"    ]. Thus, we favor management with antiparasitic therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    for 3 to 8 days) and a short course of corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    for 8 to 10 days followed by a taper) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/10\">",
"     10",
"    </a>",
"    ]. Combination therapy using both albendazole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    had more potent antiparasitic activity in a single study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Albendazole'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The long term prognosis depends on the number of seizures prior to initiation of therapy and whether residual brain calcifications are visible on subsequent radiographic evaluation; antiparasitic therapy does not appear to affect whether the lesion will calcify. Patients with a single enhancing lesion typically have resolution over the course of 6 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Multiple cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of multiple parenchymal cysts, active and inactive cysts may be present in the same patient simultaneously. Administration of antiparasitic therapy may hasten degeneration of viable cysts, thereby increasing inflammation at the site of these lesions and potentially increasing risk for seizure. Nonetheless, most favor treatment of multiple viable, parenchymal cysticerci with antiparasitic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    in two daily doses for 8 to 15 days) administered together with high-dose steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/2,8,15,37\">",
"     2,8,15,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28232?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of cysticercosis\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach is supported by a randomized, double-blind, placebo-controlled trial of 120 patients in Peru with seizures and viable parenchymal cysticerci, in which patients were treated with antiepileptic drugs and randomized to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (800 mg daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (6 mg daily for 10 days) or double placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/2\">",
"     2",
"    </a>",
"    ]. The patients were followed for 30 months or until they were seizure-free for six months after tapering of antiepileptic therapy. The patients in the treatment arm had fewer generalized seizures, although there was no significant difference in the overall number of seizures or the number of patients with seizures. The patients in the treatment arm were more likely to have radiographic resolution of intracranial cystic lesions, but there was no difference in the development of calcifications between the groups. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    and albendazole has been associated with a higher rate of radiologic resolution.",
"   </p>",
"   <p>",
"    In patients with multiple lesions (including cysticerci presumed to be viable), the viable lesions may not resolve after a single course of antiparasitic drugs, and many patients with multiple parenchymal lesions continue to have seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/2,12,38\">",
"     2,12,38",
"    </a>",
"    ]. Risk factors for seizure recurrence following withdrawal of antiepileptic drugs include: seizures prior to initiation of therapy, persistence of lesions on follow-up radiographic imaging, and presence of residual calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiparasitic medications are not helpful in the absence of viable parasites. While evidence of inflammation may be visible on imaging studies (eg, edema or contrast enhancement), there are no data that anti-inflammatory medications are beneficial in these circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cysticercal encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysticercal encephalitis (diffuse cerebral edema associated with multiple inflamed cysticerci) is a contraindication for antiparasitic therapy, since enhanced parasite killing can exacerbate host inflammatory response and lead to diffuse cerebral edema and potential transtentorial herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/10,39,40\">",
"     10,39,40",
"    </a>",
"    ]. Most cases of cysticercal encephalitis improve with corticosteroid therapy. The duration of therapy should be individualized based on the clinical and radiologic resolution of edema. Determination of antiparasitic therapy should be made once cerebral edema has resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Calcified cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic evidence of parenchymal calcifications is a significant risk factor for recurrent seizure activity; these lesions are present in about 10 percent of individuals in regions where neurocysticercosis is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/5,6,41-43\">",
"     5,6,41-43",
"    </a>",
"    ]. Seizures in these patients should be treated with antiepileptic therapy. Patients with a single seizure and no recurrence can often be tapered off of the antiepileptic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EXTRAPARENCHYMAL NCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraparenchymal forms of neurocysticercosis generally carry a higher risk for complication or death than parenchymal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Subarachnoid cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid cysticercosis (cysticercal involvement of the basilar cisterns) is the most severe form of neurocysticercosis and is frequently complicated by obstructive hydrocephalus, vasculitis and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,12,44,45\">",
"     8,12,44,45",
"    </a>",
"    ]. There are few data on optimal management, although most agree that treatment should include antiparasitic therapy, corticosteroids, and, in most cases, CSF diversion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/19\">",
"     19",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The response to standard doses of anti-parasitic agents is generally poor. Some favor treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (typically 15",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    in divided doses for at least 28 days), but cure is unusual with a single course of albendazole [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/19\">",
"     19",
"    </a>",
"    ]. Other approaches have included repeated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged therapy with albendazole, high dose albendazole, switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    , or combining albendazole with praziquantel [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammation plays an important role in the pathogenesis of subarachnoid neurocysticercosis and corticosteroids are often used in management although there are no published controlled trials on dose or duration of therapy. A reasonable approach is to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (up to 60 mg per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (up to 24 mg per day) along with the anti-parasitic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/46\">",
"     46",
"    </a>",
"    ]. The dose can often be tapered after a few weeks. However, in cases for which more prolonged steroid therapy is required, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    can be used as a steroid-sparing agent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSF diversion via ventriculostomy or placement of a ventriculo-peritoneal shunt is often warranted for management of subarachnoid NCC. There are anecdotal reports of clinical improvement with endoscopic cysticercal debulking [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,47\">",
"     8,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Giant cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid cysticerci may enlarge to &gt;5 cm in diameter, especially when located in the sylvian fissure or basilar cisterns. These giant cysticerci are usually accompanied by cerebral edema and mass effect, which should be managed with high dose corticosteroids (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ). Rarely, surgical decompression is required. When mass effect is controlled, giant cysticerci can be treated similarly to other forms of subarachnoid cysticerci [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intraventricular cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intraventricular cysts and hydrocephalus in the setting of altered mental status or impending herniation should undergo emergent management with CSF diversion via a ventriculostomy or placement of a ventriculo-peritoneal shunt.",
"   </p>",
"   <p>",
"    For patients with mild or intermittent symptoms of hydrocephalus due to intraventricular cysts, the preferred treatment is elective endoscopic removal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/8,10,29,48-51\">",
"     8,10,29,48-51",
"    </a>",
"    ]. Cysticerci in the lateral and third ventricles can be removed using a rigid endoscope. Cysticerci in the fourth ventricle may be approached using a flexible endoscope; in some cases consideration of open resection may be appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Cysticerci frequently rupture during removal, although this is not associated with adverse effects.",
"   </p>",
"   <p>",
"    Antiparasitic drugs should not be administered prior to surgery since they can weaken the cyst membrane, causing friability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adherence to the ventricular wall. Antiparasitic medications and corticosteroids are not necessary in most cases after cyst removal unless the patients have coexisting parenchymal disease. There are anecdotal reports of forgoing mechanical intervention in favor of medical treatment with antiparasitic drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticosteroids, although the efficacy of this approach for definitive management is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/55\">",
"     55",
"    </a>",
"    ], but adverse outcomes have been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of residual hydrocephalus may be managed with endoscopic foraminotomy and endoscopic third ventriculostomy; this approach may also allow debulking of cisternal cysticerci [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/48,50,56,57\">",
"     48,50,56,57",
"    </a>",
"    ]. Use of ventriculo-peritoneal shunting for treatment of residual hydrocephalus has been associated with a high rate of shunt failure, although failure may be less frequent in the setting of adjunctive therapy with corticosteroids and antiparasitic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ocular cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many patients are asymptomatic, inflammation around degenerating cysticerci can threaten vision by causing chorioretinitis, retinal detachment, or vasculitis. For this reason, ocular cysticercosis should be excluded by an ophthalmologic examination in all patients with NCC prior to initiating therapy.",
"   </p>",
"   <p>",
"    Surgical excision is warranted in the setting of intraocular cysts. In a series of 45 patients with intra-ocular cysticercosis, surgical removal of the intraocular cysticercosis was possible in all cases; reattachment of the retina was accomplished in 87 percent of 22 eyes and 67 percent recovered ambulatory vision [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cysticercal involvement of the extraocular muscles should be managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    and corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. This was illustrated in a retrospective review of 32 patients with viable extraocular muscle cysticercosis who received albendazole and steroids. All but four patients had complete resolution; the remaining had residual motility limitation but were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Spinal cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach to management of spinal cysticercosis is surgical removal, although some cases may respond to medical therapy with corticosteroids and antiparasitic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER FORMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Subcutaneous and intramuscular cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous or intramuscular cysticerci causing symptoms due to inflammation can be excised or treated with non steroidal anti-inflammatory medication. Excision is reasonable for symptomatic solitary lesions.",
"   </p>",
"   <p>",
"    Asymptomatic patients with cysticerci in subcutaneous or intramuscular sites generally do not require specific therapy; excision of single lesions can be considered. Such patients should undergo radiographic imaging of the brain to evaluate for neurocysticercosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Asymptomatic cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with an incidental radiographic finding of a nonviable cysticercus lesion in the brain do not appear to benefit from antiparasitic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with asymptomatic viable disease are extremely rare. There are no data to guide management for such cases; those with multiple cysts should be managed as discussed above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Multiple cysts'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FOLLOW-UP MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with parenchymal or subarachnoid neurocysticercosis should undergo intermittent radiographic surveillance to evaluate for resolution of the cysticerci and development of calcifications. Imaging may be performed one to two months and six months following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/12\">",
"     12",
"    </a>",
"    ]. The frequency of subsequent imaging should be individualized; once lesions have resolved follow-up imaging is less useful. Imaging should be repeated prior to discontinuing anti-epileptic drugs. New, worsening, or persistent symptoms should prompt evaluation. Antiparasitic therapy should be considered for patients with growing cysts off therapy. An alternative approach may include serial antigen-detection assays [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17865/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with intraventricular shunts should be educated to seek prompt attention for symptoms of hydrocephalus, which may occur in the setting of shunt failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for patients with symptomatic neurocysticercosis is not always straightforward and depends upon many factors including the location, number and type of cysts. Despite many uncertainties, some principles are generally agreed upon by most experts for managing specific situations:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Antiepileptic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiepileptic drug therapy should be administered for patients who present with seizures. We suggest antiepileptic therapy for patients who do not present with seizures but are at high risk for seizures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The risk of seizures appears to be highest in the setting of multiple lesions, particularly when the lesions are degenerating and are surrounded by inflammation. Calcified, inactive lesions can also be seizure foci but are not generally considered an indication for prophylactic antiepileptic therapy in otherwise asymptomatic patients.",
"     </li>",
"     <li>",
"      We typically administer antiepileptic therapy for six to twelve months after radiographic resolution of active parasitic infection, followed by a trial off of antiepileptic therapy. Recurrent seizures should prompt reinitiation of chronic antiepileptic therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antiepileptic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Determining antiparasitic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a single enhancing cyst, we suggest treatment with antiparasitic and corticosteroid therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ), given the slightly shorter duration of seizure risk and time to radiologic resolution with this approach compared expectant management (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Single lesions'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For patients with multiple cysts, we suggest treatment with antiparasitic and corticosteroid therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). However, we recommend NOT administering antiparasitic therapy for patients with diffuse cerebral edema associated with multiple inflamed cysticerci (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ); such patients should be treated with corticosteroid therapy alone. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Multiple cysts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Cysticercal encephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with calcified cysts (in the absence of viable lesions) we suggest NOT administering antiparasitic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); antiparasitic medications are not helpful in the absence of viable parasites. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Calcified cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with subarachnoid cysts, we recommend treatment with antiparasitic and corticosteroid therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The duration of therapy and choice of agents and doses need to be individualized. Those with hydrocephalus also require CSF diversion. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Extraparenchymal NCC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intraventricular or spinal cysts in anatomic sites accessible to endoscopic resection, we suggest endoscopic resection (in regions where this therapeutic modality is available) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other patients require an individualized approach including antiparasitic therapy, corticosteroid therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical intervention. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Extraparenchymal NCC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with involvement of the extraocular muscles or optic nerve we suggest antiparasitic therapy and corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with intraocular disease we suggest surgical excision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ocular cysticercosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic subcutaneous or intramuscular lesions, we suggest treatment with non-steroidal anti-inflammatory medications. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If symptoms persist, excision of solitary lesions can be considered. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Subcutaneous and intramuscular cysticercosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Initiating antiparasitic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to the initiation of therapy with antiparasitic medications or corticosteroids, screening for latent TB infection, strongyloidiasis and ocular cysticercosis should be pursued. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prior to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a determination has been made that antiparasitic therapy is indicated, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The typical dose of albendazole is 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (usually 800",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in two divided doses; taken with food to increase bioavailability). The combination of albendazole 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day along with praziquantel 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day may be more effective (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The optimal duration of therapy depends on the form of disease. For patients with a single enhancing lesion, we suggest treatment for 7 days. For patients with multiple cystic lesions, we suggest treatment for 10 to 14 days. For patients with subarachnoid disease, we suggest treatment for at least 28 days. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antiparasitic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a determination has been made that antiparasitic therapy is indicated, we recommend coadministration of corticosteroids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A typical dose is 1",
"      <span class=\"nowrap\">",
"       mg/kg/d",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or 0.1",
"      <span class=\"nowrap\">",
"       mg/kg/d",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      for 5 to 10 days followed by a rapid taper (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Anti-inflammatory therapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with altered mental status or impending herniation due to hydrocephalus associated with NCC undergo emergent CSF diversion (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This may be achieved via ventriculostomy or placement of a ventriculo-peritoneal shunt. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest endoscopic removal of intraventricular cysts for patients with hydrocephalus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Antiparasitic drugs should not be administered prior to surgery since they can weaken the cyst membrane, causing friability",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adherence to the ventricular wall. Antiparasitic medications and corticosteroids are not necessary in most cases after cyst removal unless the patients have coexisting parenchymal disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Intraventricular cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend open surgical resection for patients with giant cysticerci and life-threatening mass effect and cysticerci at sites inaccessible by flexible endoscopy (such as ocular or spinal NCC) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with parenchymal or subarachnoid neurocysticercosis should have follow-up radiographic evaluation for resolution of the cysticerci and development of calcifications. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Follow-up monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/1\">",
"      Kaushal S, Rani A, Chopra SC, Singh G. Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurol India 2006; 54:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/2\">",
"      Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004; 350:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/3\">",
"      Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994; 44:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/4\">",
"      Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 2002; 59:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/5\">",
"      Rajshekhar V, Jeyaseelan L. Seizure outcome in patients with a solitary cerebral cysticercus granuloma. Neurology 2004; 62:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/6\">",
"      Verma A, Misra S. Outcome of short-term antiepileptic treatment in patients with solitary cerebral cysticercus granuloma. Acta Neurol Scand 2006; 113:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/7\">",
"      Nash TE, Pretell EJ, Lescano AG, et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol 2008; 7:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/8\">",
"      Nash TE, Singh G, White AC, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006; 67:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/9\">",
"      Serpa JA, Yancey LS, White AC Jr. Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther 2006; 4:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/10\">",
"      Garc&iacute;a HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002; 15:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/11\">",
"      G&ouml;ngora-Rivera F, Soto-Hern&aacute;ndez JL, Gonz&aacute;lez Esquivel D, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006; 66:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/12\">",
"      Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/13\">",
"      Jung H, Hurtado M, Medina MT, et al. Dexamethasone increases plasma levels of albendazole. J Neurol 1990; 237:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/14\">",
"      Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 1998; 34:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/15\">",
"      Del Brutto OH, Roos KL, Coffey CS, Garc&iacute;a HH. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006; 145:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/16\">",
"      Singh G, Rajshekhar V, Murthy JM, et al. A diagnostic and therapeutic scheme for a solitary cysticercus granuloma. Neurology 2010; 75:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/17\">",
"      Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2003; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/18\">",
"      Bustos JA, Pretell EJ, Llanos-Zavalaga F, et al. Efficacy of a 3-day course of albendazole treatment in patients with a single neurocysticercosis cyst. Clin Neurol Neurosurg 2006; 108:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/19\">",
"      Proa&ntilde;o JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001; 345:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/20\">",
"      Garcia HH, Lescano AG, Lanchote VL, et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol 2011; 72:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/21\">",
"      Kaur S, Singhi P, Singhi S, Khandelwal N. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2009; 28:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/22\">",
"      Yee T, Barakos JA, Knight RT. High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up. West J Med 1999; 170:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/23\">",
"      Garcia HH. Antiparasitic drugs in neurocysticercosis: albendazole or praziquantel? Expert Rev Anti Infect Ther 2008; 6:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/24\">",
"      Mall RK, Agarwal A, Garg RK, et al. Short course of prednisolone in Indian patients with solitary cysticercus granuloma and new-onset seizures. Epilepsia 2003; 44:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/25\">",
"      Prakash S, Garg RK, Kar AM, et al. Intravenous methyl prednisolone in patients with solitary cysticercus granuloma: a random evaluation. Seizure 2006; 15:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/26\">",
"      Garg RK, Potluri N, Kar AM, et al. Short course of prednisolone in patients with solitary cysticercus granuloma: a double blind placebo controlled study. J Infect 2006; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/27\">",
"      Kishore D, Misra S. Short course of oral prednisolone on disappearance of lesion and seizure recurrence in patients of solitary cysticercal granuloma with single small enhancing CT lesion: an open label randomized prospective study. J Assoc Physicians India 2007; 55:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/28\">",
"      Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis 2007; 44:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/29\">",
"      Rangel-Castilla L, Serpa JA, Gopinath SP, et al. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg 2009; 80:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/30\">",
"      Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg 1987; 66:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/31\">",
"      Kelley R, Duong DH, Locke GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 2002; 50:757.",
"     </a>",
"    </li>",
"    <li>",
"     Garcia, HH, Wittner, et al. Cysticercosis. In: Tropical Infectious Diseases: Principles, Pathogens, and Practice, Guerrant, RL, Walker, DH, Weller, PF (Eds), Churchill-Livingstone, Elsevier, Philadelphia 2006. p.1289.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/33\">",
"      Colli BO, Carlotti CG Jr, Assirati JA Jr, et al. Surgical treatment of cerebral cysticercosis: long-term results and prognostic factors. Neurosurg Focus 2002; 12:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/34\">",
"      Singhi P, Jain V, Khandelwal N. Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. J Child Neurol 2004; 19:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/35\">",
"      Thussu A, Chattopadhyay A, Sawhney IM, Khandelwal N. Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. J Neurol Neurosurg Psychiatry 2008; 79:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/36\">",
"      Otte WM, Singla M, Sander JW, Singh G. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology 2013; 80:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/37\">",
"      Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010; :CD000215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/38\">",
"      Das K, Mondal GP, Banerjee M, et al. Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J Clin Neurosci 2007; 14:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/39\">",
"      Thomson AJ. Neurocysticercosis--experience at the teaching hospitals of the University of Cape Town. S Afr Med J 1993; 83:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/40\">",
"      Rangel R, Torres B, Del Bruto O, Sotelo J. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg 1987; 36:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/41\">",
"      Nash TE, Del Brutto OH, Butman JA, et al. Calcific neurocysticercosis and epileptogenesis. Neurology 2004; 62:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/42\">",
"      Rajshekhar V, Raghava MV, Prabhakaran V, et al. Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India. Neurology 2006; 67:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/43\">",
"      Garcia-Noval J, Moreno E, de Mata F, et al. An epidemiological study of epilepsy and epileptic seizures in two rural Guatemalan communities. Ann Trop Med Parasitol 2001; 95:167.",
"     </a>",
"    </li>",
"    <li>",
"     Garcia HH, Coyle CM, White AC Jr. Cysticercosis. In: Tropical Infectious Diseases: Principles, Pathogens, and Practice, 3rd, Guerrant RL, Walker DH, Weller PF (Eds), Saunders-Elsevier, Philadelphia 2011. p.815.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/45\">",
"      Garcia HH, Del Brutto OH, Nash TE, et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 2005; 72:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/46\">",
"      Garcia HH, Del Brutto OH, Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/47\">",
"      Gravori T, Steineke T, Bergsneider M. Endoscopic removal of cisternal neurocysticercal cysts. Technical note. Neurosurg Focus 2002; 12:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/48\">",
"      Bergsneider M, Holly LT, Lee JH, et al. Endoscopic management of cysticercal cysts within the lateral and third ventricles. J Neurosurg 2000; 92:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/49\">",
"      Psarros TG, Krumerman J, Coimbra C. Endoscopic management of supratentorial ventricular neurocysticercosis: case series and review of the literature. Minim Invasive Neurosurg 2003; 46:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/50\">",
"      Husain M, Jha DK, Rastogi M, et al. Neuro-endoscopic management of intraventricular neurocysticercosis (NCC). Acta Neurochir (Wien) 2007; 149:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/51\">",
"      Suri A, Goel RK, Ahmad FU, et al. Endoscopic excision of intraventricular neurocysticercosis in children: a series of six cases and review. Childs Nerv Syst 2008; 24:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/52\">",
"      Zymberg ST, Paiva Neto MA, Gorgulho AA, Cavalheiro S. Endoscopic approach to fourth ventricle cysticercosis. Arq Neuropsiquiatr 2003; 61:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/53\">",
"      Torres-Corzo J, Rodriguez-della Vecchia R, Rangel-Castilla L. Bruns syndrome caused by intraventricular neurocysticercosis treated using flexible endoscopy. J Neurosurg 2006; 104:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/54\">",
"      Husain M, Rastogi M, Jha DK, et al. Endoscopic transaqueductal removal of fourth ventricular neurocysticercosis with an angiographic catheter. Neurosurgery 2007; 60:249.",
"     </a>",
"    </li>",
"    <li>",
"     Bergsneider, M, Nieto, JH. Endoscopic management of intraventricular cysticercosis. In: Taenia solium cysticercosis: from basic to clinical science, Singh, G, Prabhakar, S (Eds), CABI Publishing, Oxford 2002. p.399.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/56\">",
"      Psarros TG, Coimbra C. Endoscopic third ventriculostomy for patients with hydrocephalus and fourth ventricular cysticercosis: a review of five cases. Minim Invasive Neurosurg 2004; 47:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/57\">",
"      Lapergue B, Hosseini H, Liance M, et al. Hydrocephalus and racemose cysticercosis: surgical alternative by endoscopic third ventriculostomy. Neurochirurgie 2005; 51:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/58\">",
"      Sharma T, Sinha S, Shah N, et al. Intraocular cysticercosis: clinical characteristics and visual outcome after vitreoretinal surgery. Ophthalmology 2003; 110:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/59\">",
"      Murthy R, Samant M. Extraocular muscle cysticercosis: clinical features and management outcome. Strabismus 2008; 16:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/60\">",
"      Sundaram PM, Jayakumar N, Noronha V. Extraocular muscle cysticercosis - a clinical challenge to the ophthalmologists. Orbit 2004; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/61\">",
"      Bandres JC, White AC Jr, Samo T, et al. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis 1992; 15:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17865/abstract/62\">",
"      White AC Jr. New developments in the management of neurocysticercosis. J Infect Dis 2009; 199:1261.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5681 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17865=[""].join("\n");
var outline_f17_28_17865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antiepileptic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antiparasitic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Albendazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Praziquantel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anti-inflammatory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prior to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PARENCHYMAL NCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Single lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Multiple cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cysticercal encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Calcified cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EXTRAPARENCHYMAL NCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Subarachnoid cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Giant cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intraventricular cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ocular cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Spinal cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER FORMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Subcutaneous and intramuscular cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Asymptomatic cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FOLLOW-UP MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Antiepileptic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Determining antiparasitic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Initiating antiparasitic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28232?source=related_link\">",
"      Clinical manifestations and diagnosis of cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15413?source=related_link\">",
"      Epidemiology, transmission and prevention of cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_28_17866="Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults";
var content_f17_28_17866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/28/17866/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17866/contributors\">",
"     Sam Ahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17866/contributors\">",
"     Lloyd Mayer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17866/contributors\">",
"     Charlotte Cunningham-Rundles, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/28/17866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17866/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/28/17866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/28/17866/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/28/17866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common variable immunodeficiency (CVID, MIM 240500) is a primary immunodeficiency disorder characterized by impaired B cell differentiation with defective immunoglobulin production. It is the most prevalent form of severe antibody deficiency affecting both children and adults. \"Variable\" refers to the heterogeneous clinical manifestations of this disorder, which include recurrent infections, chronic lung disease, autoimmune disorders, gastrointestinal disease, and a heightened susceptibility to lymphoma. CVID is not a single disease, but rather a collection of hypogammaglobulinemia syndromes resulting from many genetic defects. In a small subset of patients, specific molecular defects have been identified; although in most cases, these causes are as yet unknown.",
"   </p>",
"   <p>",
"    The clinical manifestations, epidemiology, evaluation, and diagnosis of CVID will be discussed here, with a focus on presentation in adult patients. Issues that are particularly relevant to the clinical manifestations and diagnosis in children are reviewed separately. The clinical manifestations, pathogenesis, and treatment in adults are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link\">",
"     \"Common variable immunodeficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link\">",
"     \"Treatment and prognosis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191858\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVID is defined by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Markedly reduced serum concentrations of IgG, in combination with low levels of IgA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM",
"     </li>",
"     <li>",
"      Poor or absent response to immunizations",
"     </li>",
"     <li>",
"      An absence of any other defined immunodeficiency state",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191865\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVID is estimated to affect as many as 1 in 25,000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. There is some evidence of higher prevalence among individuals of northern European descent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. An internet-based database of patients with primary immunodeficiency has been established by the European Society for Immunodeficiencies (ESID), in which CVID is the most common diagnosis, affecting approximately 20 percent of registered patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age of onset is typically after puberty and before 30 years of age, with some evidence of a bimodal distribution demonstrating peaks between 1 and 5 years, and 18 and 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/3\">",
"     3",
"    </a>",
"    ]. In one study of 248 patients with CVID, the average age at the onset of symptoms was 23 and 28 years for males and females, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4\">",
"     4",
"    </a>",
"    ]. While the onset of clinical symptoms may be apparent before the age of four, the diagnosis of CVID is not definitively made until further immune maturation has occurred, and other immune defects can be considered.",
"   </p>",
"   <p>",
"    The clinical manifestations of CVID affect multiple organ systems, and patients often have been evaluated by several specialists by the time they are diagnosed. Perhaps partly for this reason, delayed recognition of this disease is common. In the above study, there was an average of five to seven years between onset of symptoms and diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Etiologic and genetic factors underlying CVID are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193444\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVID is associated with a broad spectrum of disorders, including infections, chronic lung disease, autoimmune disease, gastrointestinal and liver disorders, granulomatous infiltration, splenomegaly, and an increased risk of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/2-4,8-12\">",
"     2-4,8-12",
"    </a>",
"    ]. In a series of 473 patients, the following disorders were diagnosed over the course of 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections (94 percent)",
"     </li>",
"     <li>",
"      Hematologic or organ-specific autoimmunity (29 percent)",
"     </li>",
"     <li>",
"      Chronic lung disease (29 percent)",
"     </li>",
"     <li>",
"      Bronchiectasis (11 percent)",
"     </li>",
"     <li>",
"      Gastrointestinal inflammatory disease (15 percent)",
"     </li>",
"     <li>",
"      Malabsorption (6 percent)",
"     </li>",
"     <li>",
"      Granulomatous disease (10 percent)",
"     </li>",
"     <li>",
"      Liver",
"      <span class=\"nowrap\">",
"       disease/hepatitis",
"      </span>",
"      (9 percent)",
"     </li>",
"     <li>",
"      Lymphoma (8 percent)",
"     </li>",
"     <li>",
"      Other cancers (7 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193458\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinopulmonary and gastrointestinal infections are common among patients with CVID. In the large series mentioned above, 32 percent of patients had infections as their only manifestation of CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25083002\">",
"    <span class=\"h3\">",
"     Most common pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients develop bacterial infections. Some patients are susceptible to enteroviruses and protozoa (ie, giardiasis), as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25083082\">",
"    <span class=\"h4\">",
"     Other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell dysfunction is variable in patients with CVID and unusual or opportunistic infections with viral and fungal pathogens are uncommon. However, Cryptosporidia, Pneumocystis pneumonia, and severe herpes zoster (shingles) have been reported, even in patients who do not have laboratory abnormalities indicative of decreased T cell numbers or depressed T cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,9,14,15\">",
"     4,9,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25083016\">",
"    <span class=\"h3\">",
"     Sinopulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinopulmonary infections, including pneumonia, bronchitis, and sinusitis, as well as otitis and conjunctivitis, are observed in the majority of patients with CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,5,12\">",
"     4,5,12",
"    </a>",
"    ]. These infections may be acute, chronic, or recurrent. Patients are particularly susceptible to infection with Pneumococcus, Hemophilus, and Mycoplasma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,16,17\">",
"     4,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumonia - Over three-quarters of patients have at least one episode of bacterial pneumonia prior to diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,18\">",
"       4,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rhinosinusitis - Both acute and chronic rhinosinusitis are very common, particularly in untreated CVID patients. Often multiple pathogens are responsible, including both bacteria and viruses, with rhinovirus being the most common [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/19\">",
"       19",
"      </a>",
"      ]. It is unclear if patients with CVID suffer from more frequent or severe infections with viruses causing common colds.",
"     </li>",
"     <li>",
"      Conjunctivitis - Chronic or recurrent conjunctivitis in patients with CVID is principally due to non-encapsulated H. influenzae [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25083192\">",
"    <span class=\"h3\">",
"     Gastrointestinal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic giardiasis causing refractory diarrhea, malabsorption,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss has been reported in patients with CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/7,20,21\">",
"     7,20,21",
"    </a>",
"    ]. Other infections causing chronic diarrhea include cytomegalovirus and cryptosporidium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,22-24\">",
"     4,22-24",
"    </a>",
"    ]. However, many gastrointestinal symptoms cannot be attributed to an infectious etiology. (See",
"    <a class=\"local\" href=\"#H9597804\">",
"     'Gastrointestinal disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25083250\">",
"    <span class=\"h3\">",
"     Other infectious disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other infectious disorders reported in patients with CVID include septic arthritis, sepsis, meningitis (both bacterial and viral), and meningoencephalitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Septic arthritis &ndash; Streptococci or mycoplasma can cause septic arthritis (as well as respiratory infections) in patients with CVID [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/12,25\">",
"       12,25",
"      </a>",
"      ]. The presentation can range from acute monoarthritis that responds rapidly to antibiotic therapy, or for mycoplasma, to erosive, chronic polyarthritis that is resistant to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"       \"Septic arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial meningitis and sepsis were reported in CVID patients, mostly before treatment with immunoglobulin therapy became available [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/2-4,7-11,26\">",
"       2-4,7-11,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There have reports of patients with enterovirus infection (particularly echovirus), either presenting with classical meningoencephalitic symptoms (sometimes accompanied by dermatomyositis-like vasculitis), or as cognitive impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193479\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lung disease is a common problem in patients with CVID and can lead to recurrent hospitalizations and significant morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,12,18,30\">",
"     4,12,18,30",
"    </a>",
"    ]. It has historically been a leading cause of death in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/13,31\">",
"     13,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately one-third have chronic lung disease by the time of diagnosis. For example, in one study of 224 patients, 34 percent had chronic lung disease at the time of diagnosis, which increased to 46 percent during a mean follow-up of 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/32\">",
"     32",
"    </a>",
"    ]. In another large series, of 248 patients, 27 percent had either bronchiectasis, or restrictive or obstructive lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8458064\">",
"    <span class=\"h3\">",
"     Types of lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of pulmonary disease are seen with regularity in patients with CVID:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive disease: An obstructive pattern on spirometry in patients with CVID can accompany asthma, bronchiectasis, or other lung processes. Therefore, additional evaluation, such as bronchodilator challenge to demonstrate reversibility or bronchial provocation testing, may be needed to diagnose asthma conclusively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/33\">",
"       33",
"      </a>",
"      ]. Bronchiectasis in CVID is postulated to result from recurrent pulmonary infections in addition to unregulated inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"       \"Treatment of bronchiectasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Restrictive disease: Restrictive changes on pulmonary function testing are likely to indicate that inflammatory disease of the lung developed. It may result from lymphocytic or granulomatous infiltrates or both. On pulmonary imaging, reticular, nodular, or ground glass opacities may be the features of interstitial lung disease in patients with CVID.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Granulomatous/lymphocytic",
"      </span>",
"      infiltrative disease: The prevalence of granulomatous lung disease usually with lymphocytic infiltrates is increased in patients with CVID. The presence of any of these disorders has been termed granulomatous-lymphocytic interstitial lung disease (GLILD) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. In one retrospective study, 10 percent of 18 patients had interstitial disease on high-resolution CT, which was associated with systemic granulomatous disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/36\">",
"       36",
"      </a>",
"      ]. Thirteen patients had fine to coarse diffuse reticulation, and features of fibrosis and nodules were found in eight [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/31,37,38\">",
"       31,37,38",
"      </a>",
"      ]. Human herpes virus type 8 (HHV8) was implicated in the pathogenesis of GLILD in one study, in which polymerase chain reactions studies for HHV8 genome in peripheral blood monocytes was positive in 6 of 9 CVID patients with GLILD, compared with 1 of 21 CVID patients without GLILD [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/39\">",
"       39",
"      </a>",
"      ]. However, these findings have not been replicated.",
"     </li>",
"     <li>",
"      Follicular bronchiolitis, lymphoid hyperplasia, and lymphoid interstitial pneumonia: These are also commonly associated with lung disease in CVID.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9597804\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal disease is identified in approximately 20 percent of CVID patients and may be the presenting disorder in some [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,40,41\">",
"     4,40,41",
"    </a>",
"    ]. Diarrhea is the most common symptom, with malabsorption and weight loss also reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/22,42\">",
"     22,42",
"    </a>",
"    ]. Vitamin and electrolyte deficiencies may result in severe cases. Specific disorders include (in decreasing order of prevalence):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammatory bowel disease (ulcerative colitis, ulcerative proctitis, or Crohn's-like disease, microscopic colitis)",
"     </li>",
"     <li>",
"      Sprue-like illness with flat villi",
"     </li>",
"     <li>",
"      Nodular lymphoid hyperplasia (",
"      <a class=\"graphic graphic_picture graphicRef80570 \" href=\"UTD.htm?33/4/33870\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pernicious anemia",
"     </li>",
"     <li>",
"      Bacterial overgrowth",
"     </li>",
"     <li>",
"      Protein-losing enteropathy",
"     </li>",
"     <li>",
"      Nonspecific malabsorption",
"     </li>",
"     <li>",
"      Gastrointestinal lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Predisposing conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology of many of these gastrointestinal disorders in not understood, although defects in cellular immunity, rather than antibody deficiency alone, appear to predispose patients to such illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/23,43,44\">",
"     23,43,44",
"    </a>",
"    ]. Similar to the relationship seen with memory B cells and lung disease, patients with very low total memory B cells and low switched memory B cells appear more likely to develop malabsorption or chronic diarrhea than patients with normal memory B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Variable laboratory abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193493\">",
"    <span class=\"h2\">",
"     Autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune conditions are diagnosed in almost one-quarter of CVID patients and can be the presenting disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Autoimmunity is a manifestation of immune dysregulation, although the specific mechanisms for this heightened susceptibility in CVID are not known. The most frequently diagnosed disorders are (",
"    <a class=\"graphic graphic_table graphicRef81925 \" href=\"UTD.htm?1/38/1644\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,13,48,49\">",
"     4,13,48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune hemolytic anemia and immune thrombocytopenia (ITP) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/46,50,51\">",
"       46,50,51",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rheumatoid arthritis and rheumatoid-like arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/52\">",
"       52",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pernicious anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,53\">",
"       4,53",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autoimmune thyroiditis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vitiligo [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Autoimmune hematologic disorders are the most common autoimmune conditions in these patients. A review of 326 CVID patients found that 11 percent had a history of immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), or Evans' syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/46\">",
"     46",
"    </a>",
"    ]. Approximately one-half of these developed hematologic autoimmune disease before or concurrent with the diagnosis of CVID. A small case control study suggested that patients presenting with AIHA initially may represent a distinct phenotype, with lower rates of recurrent infections, but higher rates of splenomegaly, other autoimmune conditions, and lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/51\">",
"     51",
"    </a>",
"    ]. Autoimmune disorders in children with CVID are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link&amp;anchor=H10572417#H10572417\">",
"     \"Common variable immunodeficiency in children\", section on 'Autoimmune disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CVID may also be identified in rare patients who were previously diagnosed with systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/56\">",
"     56",
"    </a>",
"    ]. In most cases, the SLE appeared to precede the CVID, and it remains unclear if immunosuppressive or glucocorticoid therapy in SLE patients can cause the development of hypogammaglobulinemia and immune defects, or if the two conditions are arising from a common underlying defect.",
"   </p>",
"   <p>",
"    Other autoimmune conditions that have been reported in CVID patients include inflammatory bowel disease, juvenile idiopathic arthritis, Sj&ouml;gren's disease, vitiligo, reactive arthritis (formerly Reiter syndrome), autoimmune hepatitis, and autoimmune neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193500\">",
"    <span class=\"h2\">",
"     Granulomatous infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CVID may develop noncaseating granulomas in the lymphoid or solid organs, including the lungs, lymph nodes, spleen, liver, intestine, brain, eyes, or skin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. It is estimated that 8 to 20 percent of CVID patients have some form of granulomatous disease, although the prevalence is probably underappreciated since most tissues are not biopsied [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4,61\">",
"     4,61",
"    </a>",
"    ]. Common presentations include lymphadenopathy, splenomegaly, and pulmonary symptoms. Patients with granulomatous disease in CVID appear to have higher rates of autoimmune disorders as well, such as immune thrombocytopenia (ITP) and hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A sarcoid-like disorder with granulomatous infiltration of the liver and lungs and variable elevations in angiotensin converting enzyme (ACE) levels is recognized in CVID patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/16,62,63\">",
"     16,62,63",
"    </a>",
"    ]. Note that elevations in ACE are not specific and are found in other immune deficient subjects with no history of granuloma, as well as approximately 75 percent of patients with sarcoidosis. One series found 8 cases of CVID among 80 patients with sarcoidosis, with 22 other cases reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/62\">",
"     62",
"    </a>",
"    ]. Therefore, patients with apparent sarcoidosis who are hypogammaglobulinemic and have recurrent infections should be evaluated for CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of noncaseating granulomas in CVID is not known. An unusual TNF polymorphism was found in increased numbers, but any effect on TNF levels or usage was not examined. An abnormal CD8+ T cell response to cytomegalovirus has also been detected in patients with CVID and inflammatory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193507\">",
"    <span class=\"h2\">",
"     Allergic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CVID can have signs and symptoms consistent with allergic diseases, especially allergic rhinitis and asthma. However, diagnosis may not be straightforward because despite a consistent clinical presentation, some patients have low or undetectable levels of serum IgE. One study demonstrated that some patients with symptoms suggestive of allergic asthma had low or undetectable total IgE, negative in vitro tests for allergen-specific IgE, and yet developed symptoms to bronchoprovocation tests with allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193514\">",
"    <span class=\"h2\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenomegaly is common in CVID patients, although the pathogenesis of this finding is not known. One report of 224 CVID patients showed 26 percent had an enlarged spleen by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193521\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients have significant liver dysfunction, with elevations in alkaline phosphatase being common in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/66\">",
"     66",
"    </a>",
"    ]. Hepatitis B and C virus infection, primary biliary cirrhosis, and granulomatous liver disease have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4\">",
"     4",
"    </a>",
"    ]. In a series of CVID patients with evidence of liver dysfunction, biopsies revealed nodular regenerative hyperplasia in many [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. These patients appeared to have higher rates of autoimmune disease and non-celiac enteropathy, compared to CVID patients without liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37095?source=see_link\">",
"     \"Nodular regenerative hyperplasia of the liver\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193528\">",
"    <span class=\"h2\">",
"     Malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of malignancies is reported in CVID. In a large European study, the relative risk of cancer at all sites was 1.8, with an absence of an increased risk among relatives, suggesting that the effect was due to CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/68\">",
"     68",
"    </a>",
"    ]. Non-Hodgkin lymphomas (NHL) are most common. In another large European collaborative study of 334 CVID patients, having a form of polyclonal lymphocytic infiltration was associated with a fivefold increased risk of lymphoid malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, there was a correlation between higher serum IgM levels and the eventual development of either polyclonal lymphocytic infiltration or lymphoid malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193535\">",
"    <span class=\"h3\">",
"     Non-Hodgkin lymphomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;NHLs occur at a markedly increased rate among patients with CVID, although the precise incidence is difficult to determine. In a large clinical study of 248 patients with CVID, 8 percent of patients developed NHL over variable periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4\">",
"     4",
"    </a>",
"    ]. Another study estimated that females had a 438-fold increased risk of developing NHL compared to the age-adjusted expected incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/69\">",
"     69",
"    </a>",
"    ]. Clusters of NHL within families affected by CVID have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NHLs that occur in patients with CVID are mostly extranodal in origin, well differentiated, and of B cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association exists between NHL and other congenital immunodeficiency diseases, although principally those with prominent T cell defects. These include ataxia-telangiectasia, Wiskott-Aldrich syndrome, X-linked lymphoproliferative disease, and severe combined immune deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193542\">",
"    <span class=\"h3\">",
"     Gastric cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older studies, there was an increased risk of gastric cancer in CVID patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/3,4,32,72\">",
"     3,4,32,72",
"    </a>",
"    ]. This may be related to the increased frequency of pernicious anemia or Helicobacter pylori infection, as a study of 34 CVID patients with dyspepsia found that 41 percent had biopsy-proven Helicobacter pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/40\">",
"     40",
"    </a>",
"    ]. In these patients, the infection was significantly associated with multifocal atrophic gastritis, which is associated with gastric carcinoma. Common presenting symptoms of gastric cancer include abdominal pain, weight loss, and dyspepsia. However, the incidence of this cancer may be decreasing, as suggested by a 2010 study of 476 patients, in which gastric cancer, non-Hodgkin lymphoma, and Hodgkin's disease were diagnosed in 0.6, 0.8, and 6.7 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193549\">",
"    <span class=\"h2\">",
"     Neurologic degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of progressive neurodegeneration, for which no etiology could be identified, have been reported in a few patients with CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/29\">",
"     29",
"    </a>",
"    ]. Possible explanations include a disorder directly related to CVID itself, an autoimmune disease, or an undefined infectious agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196168\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial laboratory evaluation of patients with CVID involves the measurement of immunoglobulin levels, the demonstration of impaired responses to vaccinations, and exclusion of other causes of these abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2193210\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of patients with CVID may be normal, or there may be signs and symptoms of chronic illness (eg, failure to thrive or growth retardation in children, weight loss in adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/7\">",
"     7",
"    </a>",
"    ]. Other common abnormalities include nasal discharge or congestion signifying chronic sinusitis, scarring of the tympanic membranes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    digital clubbing signifying chronic pulmonary or liver disease. Oral thrush is uncommon. Additional findings that may be noted in some patients with CVID include lymphadenopathy, splenomegaly, arthritis, scleritis, and skin findings associated with autoimmune disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2193234\">",
"    <span class=\"h2\">",
"     Indications for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient&rsquo;s history and physical examination raise concern about a possible diagnosis of CVID, immunoglobulin levels should be evaluated initially, as described in this section. Referral to a clinical immunologist is indicated, whenever possible, to assess vaccine responsiveness and exclude other causes of hypogammaglobulinemia. Immunology specialists can also determine the most appropriate therapies (such as prophylactic antibiotics and immune globulin) and help monitor the patient for associated disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1196176\">",
"    <span class=\"h2\">",
"     Routine laboratories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CVID do not generally have abnormalities in routine laboratories, such as complete blood counts, serum chemistries, electrolytes, or urinalysis, in the absence of a specific associated condition. Occasionally, reductions in serum globulins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total protein level may be seen, and a modest lymphopenia may develop over time, but these are not reliable abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunoglobulin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum immunoglobulin levels are markedly abnormal in patients with CVID. Serum IgG should be below the lower limit of normal and generally under 400",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    In addition, IgA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low IgM should be below the lower limit of normal. One-half of patients have no detectable immunoglobulin. Most laboratories define the normal reference range as two standard deviations or confidence intervals above and below the age-adjusted mean.",
"   </p>",
"   <p>",
"    A study of 224 CVID patients reported the following mean immunoglobulin levels at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgG of 258",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (with a normal reference range of 768 to 1728",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      IgA of 28",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (normal range: 99 to 396",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      IgM of 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (normal range: 38 to 266",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunoglobulin levels should be repeated to confirm that the values are persistently low and that a laboratory error has not occurred. Repeating levels once is sufficient if the patient is in their usual state of health. If there is a concomitant illness that could cause secondarily low immunoglobulin levels (eg, nephrotic syndrome or protein losing enteropathy), then the measurement should be repeated approximately three months after resolution of the illness. In contrast, neither acute infection, such as pneumonia, nor short-term administration of systemic glucocorticoids, should significantly reduce or increase immunoglobulin levels. However, chronic systemic glucocorticoids may reduce serum IgG levels, as reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few patients with CVID will demonstrate marginally low levels of IgG, or IgG subclass deficiencies, with borderline or low levels of IgA and then progress to CVID with more complete losses of IgA and IgM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link&amp;anchor=H3396155#H3396155\">",
"     \"IgG subclass deficiency\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CVID may have low, normal, or increased levels of IgM. However, significantly elevated levels of IgM should prompt consideration of alternative diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=see_link\">",
"     \"Hyperimmunoglobulin M syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Absence of very low levels of natural antibodies, such as isohemagglutinins, is common. Isohemagglutinins are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vaccine response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with reduced immune globulin levels should be assessed for antibody response to both protein and polysaccharide-based vaccines, unless antibody levels are very low (eg, IgG &lt;200",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    or undetectable (in which case vaccine response can be assumed to be deficient). Acute illness does not generally affect vaccine responsiveness, nor does systemic glucocorticoids therapy, particularly if the daily dose is lower than about 40 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibody responses to a combination of vaccines are usually examined, such as tetanus, diphtheria, and polysaccharide pneumococcal vaccine. Patients with CVID generally show impaired responses to both protein and polysaccharide-based vaccines. Evaluation of vaccine response is part of the diagnosis of many immunodeficiencies and is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"     \"Assessing the immunologic response to vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Variable laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with CVID have normal numbers of circulating T and B lymphocytes. However, most patients have somewhat reduced levels of circulating memory B cells (CD27+ B cells) and especially low levels of isotype switched memory B cells (CD27+ IgD- IgM-) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/32,61\">",
"     32,61",
"    </a>",
"    ]. Some have impaired T cell function. Abnormal cytokine levels have also been described. These findings are not currently used in diagnosis and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link&amp;anchor=H15#H15\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\", section on 'Common Variable Immunodeficiency (CVID)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report of 18 CVID patients found that those with reduced total memory B cells (CD27+ B cells) and very low numbers of switched memory B cells (CD27+IgM-IgD-) were more likely to have chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/45\">",
"     45",
"    </a>",
"    ]. Over 50 percent of the study group had some form of chronic lung disease, compared to none in a group with normal levels of switched memory B cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Molecular analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular analysis is not required for diagnosis. Genome-wide association identifies diverse causes of CVID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/74\">",
"     74",
"    </a>",
"    ]. The different molecular defects that have been reported in patients with CVID are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular testing is sometimes useful for excluding other immunodeficiencies that arise from known genetic defects, such as some of the causes of hyper IgM syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=see_link\">",
"     \"Hyperimmunoglobulin M syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CVID can be assigned to a patient over age four who demonstrates",
"    <strong>",
"     all",
"    </strong>",
"    of the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/53,75,76\">",
"     53,75,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly reduced total serum concentrations of IgG",
"     </li>",
"     <li>",
"      Low IgA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM",
"     </li>",
"     <li>",
"      Poor or absent response to immunization",
"     </li>",
"     <li>",
"      The absence of any other defined immunodeficiency state (ie, CVID is a diagnosis of exclusion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of hypogammaglobulinemia, the primary laboratory feature of common variable immunodeficiency, is reviewed in this section. There are several other primary immunodeficiency disorders that must be excluded in children, and these are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link&amp;anchor=H650981#H650981\">",
"     \"Common variable immunodeficiency in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypogammaglobulinemia may be classified as primary or secondary. In adults, secondary causes of hypogammaglobulinemia are far more common than primary causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19776367\">",
"    <span class=\"h2\">",
"     Secondary hypogammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of conditions are associated with secondary hypogammaglobulinemia due to either decreased production or increased loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19776374\">",
"    <span class=\"h3\">",
"     Decreased production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased production of immunoglobulins can be seen with the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs (most commonly immunosuppressants, such as glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy, and anti-epileptics). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"       \"Glucocorticoid effects on the immune system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"       \"Secondary immune deficiency induced by drugs and biologics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignancy and pre-malignant disorders (such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, or Waldenstrom&rsquo;s macroglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/77\">",
"       77",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Systemic illnesses causing bone marrow suppression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"       \"Secondary immune deficiency due to miscellaneous causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thymoma with hypogammaglobulinemia (Good syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/78\">",
"       78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical presentation and management of thymoma and thymic carcinoma\", section on 'Immunodeficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is our approach to evaluate for secondary causes of hypogammaglobulinemia if a thorough history and physical examination reveals suggestive signs or symptoms, rather than as a matter of course. As an example, we would request an abdominal, chest, or CT to exclude lymphoma if a patient reported fever or weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19776381\">",
"    <span class=\"h3\">",
"     Increased loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased loss of immunoglobulins may result from protein-losing enteropathies, such as intestinal lymphangiectasia, nephrotic syndrome, burns, and other traumas leading to loss of fluids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link\">",
"     \"Secondary immune deficiency due to miscellaneous causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary hypogammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other primary immunodeficiencies in which significant reductions of IgG, accompanied by and either IgA or IgM deficiency or excess, may be seen. In children, several additional disorders should be excluded, as discussed separately. The discussion here is focused on adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link&amp;anchor=H650981#H650981\">",
"     \"Common variable immunodeficiency in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14472870\">",
"    <span class=\"h3\">",
"     IgG subclass deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency in IgG1 can cause general hypogammaglobulinemia, because IgG1 comprises nearly two-thirds of the total serum IgG. IgG2 subclass deficiencies can also lead to mild deficiency of serum IgG with poor vaccine response. Subclass deficiencies can also occur in conjunction with IgA deficiency and some patients demonstrate poor vaccine response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link&amp;anchor=H6#H6\">",
"     \"IgG subclass deficiency\", section on 'IgG1 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14472930\">",
"    <span class=\"h3\">",
"     Hyper IgM syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyper IgM syndromes (HIGM) can arise from defects of CD40 ligand, an X-linked disease in which loss of isotype switch from IgM to IgA or IgG does not occur. Other causes of hyper IgM syndrome are rare genetic defects in the nucleic acid modifying enzymes called activation induced cytidine deaminase (AICDA or AID) or uracil nucleoside glycosylase (UNG). Class-switching cannot occur without functional AICDA or UNG, therefore B cells can only produce appreciable quantities of IgM. Patients with AICDA and UNG deficiencies generally present with the recurrent and severe sinopulmonary infections with encapsulated bacteria that are characteristic of antibody deficiencies. Gastrointestinal infections (including Giardiasis), bacterial meningitis, viral encephalitis, and severe hepatitis B infections have also been observed, and patients are susceptible to lymph node hyperplasia and autoimmune disorders.",
"   </p>",
"   <p>",
"    Among those with CD40 ligand, AICDA and UNG deficiencies, IgG levels are generally &lt;200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    while IgA is &lt;20",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and IgM ranges from 100 to 3700",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    IgG specific antibody responses are nonexistent. Numbers of T and B cells in the circulation are normal, and T cell function is intact. Tests for CD40 ligand, AICDA and UNG deficiency are commercially available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=see_link\">",
"     \"Hyperimmunoglobulin M syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14473235\">",
"    <span class=\"h3\">",
"     Combined immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other combined immunodeficiencies that may mimic clinical or laboratory features of CVID and can present after childhood include milder forms of adenosine deaminase deficiency (ADA), hypomorphic recombination activating gene (RAG) mutations, and Artemis defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Immune Deficiency Foundation (",
"    <a class=\"external\" href=\"file://www.primaryimmune.org/\">",
"     www.primaryimmune.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/79\">",
"     79",
"    </a>",
"    ] and the Jeffrey Modell Foundation (",
"    <a class=\"external\" href=\"file://www.info4pi.org/jmf\">",
"     www.info4pi.org/jmf",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/28/17866/abstract/80\">",
"     80",
"    </a>",
"    ] have links and information for patients about common variable immunodeficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common variable immunodeficiency (CVID) is the most common form of severe antibody deficiency affecting both children and adults. The characteristic immune defect in CVID is impaired B cell differentiation with defective production of immunoglobulin. CVID is defined by low total serum concentrations of IgG, as well as low IgA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM, poor or absent response to immunization, and the absence of any other defined immunodeficiency state. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1191858\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Age of onset is variable. Twenty percent of patients are diagnosed before the age of 20 years, but more typically, the diagnosis is made between the ages of 20 and 40 years of age. Delayed recognition is common. (See",
"      <a class=\"local\" href=\"#H1191865\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial infections of the sinopulmonary tract, particularly sinusitis and pneumonia, are experienced by most patients with CVID. Opportunistic and unusual infections are uncommon, but do occur. (See",
"      <a class=\"local\" href=\"#H1193458\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic lung diseases, especially bronchiectasis, are seen in 30 to 50 percent of patients, and represent an important cause of morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H1193479\">",
"       'Pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal disease is present in about 20 percent of CVID patients, with a variety of different disorders described. The pathophysiology of most of these disorders is not known. Chronic diarrhea is the most common presenting gastrointestinal symptom. Chronic infections with giardia, cytomegalovirus, and cryptosporidium are also reported. (See",
"      <a class=\"local\" href=\"#H9597804\">",
"       'Gastrointestinal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One-quarter of patients with CVID develop autoimmune conditions, particularly hemolytic anemia, thrombocytopenia, and rheumatoid arthritis, and an estimated 8 to 20 percent have some form of granulomatous disease. (See",
"      <a class=\"local\" href=\"#H1193493\">",
"       'Autoimmune disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1193500\">",
"       'Granulomatous infiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CVID are at increased risk for malignancies, and have a particular susceptibility to non-Hodgkin lymphomas and gastric cancers. (See",
"      <a class=\"local\" href=\"#H1193528\">",
"       'Malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunoglobulin levels of IgG are below the lower limit of normal, in combination with low IgA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM. In addition, responses to both protein and polysaccharide-based vaccines are impaired. (See",
"      <a class=\"local\" href=\"#H1196168\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various forms of primary and secondary hypogammaglobulinemia must be excluded before the diagnosis of CVID can be assigned. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/1\">",
"      Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/2\">",
"      Hammarstr&ouml;m L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 2000; 120:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/3\">",
"      Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/4\">",
"      Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/5\">",
"      Oksenhendler E, G&eacute;rard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/6\">",
"      Gathmann B, Grimbacher B, Beaut&eacute; J, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol 2009; 157 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/7\">",
"      Urschel S, Kayikci L, Wintergerst U, et al. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr 2009; 154:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/8\">",
"      Spickett GP, Farrant J, North ME, et al. Common variable immunodeficiency: how many diseases? Immunol Today 1997; 18:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/9\">",
"      Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 1989; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/10\">",
"      Sneller MC, Strober W, Eisenstein E, et al. NIH conference. New insights into common variable immunodeficiency. Ann Intern Med 1993; 118:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/11\">",
"      JANEWAY CA, APT L, GITLIN D. Agammaglobulinemia. Trans Assoc Am Physicians 1953; 66:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/12\">",
"      Webster ADB. Common Variable Immunodeficiency. Immunol Allergy Clin North Am 2001; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/13\">",
"      Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/14\">",
"      Esolen LM, Fasano MB, Flynn J, et al. Pneumocystis carinii osteomyelitis in a patient with common variable immunodeficiency. N Engl J Med 1992; 326:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/15\">",
"      Kaczmarski RS, Webster AD, Moxham J, et al. CD4+ lymphocytopenia due to common variable immunodeficiency mimicking AIDS. J Clin Pathol 1994; 47:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/16\">",
"      Webster AD, Taylor-Robinson D, Furr PM, Asherson GL. Mycoplasmal (ureaplasma) septic arthritis in hypogammaglobulinaemia. Br Med J 1978; 1:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/17\">",
"      Roifman CM, Rao CP, Lederman HM, et al. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med 1986; 80:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/18\">",
"      Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 2007; 98:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/19\">",
"      Kainulainen L, Suonp&auml;&auml; J, Nikoskelainen J, et al. Bacteria and viruses in maxillary sinuses of patients with primary hypogammaglobulinemia. Arch Otolaryngol Head Neck Surg 2007; 133:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/20\">",
"      Onbai K, G&uuml;nar F, Sin AZ, et al. Common variable immunodeficiency (CVID) presenting with malabsorption due to giardiasis. Turk J Gastroenterol 2005; 16:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/21\">",
"      Sawatzki M, Peter S, Hess C. Therapy-resistant diarrhea due to Giardia lamblia in a patient with common variable immunodeficiency disease. Digestion 2007; 75:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/22\">",
"      Washington K, Stenzel TT, Buckley RH, Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol 1996; 20:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/23\">",
"      Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis 1997; 8:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/24\">",
"      Khodadad A, Aghamohammadi A, Parvaneh N, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci 2007; 52:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/25\">",
"      Franz A, Webster AD, Furr PM, Taylor-Robinson D. Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. Br J Rheumatol 1997; 36:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/26\">",
"      Hill LE. Hypogammaglobulinaemia in the United Kingdom. 3. Clinical features of hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B) 1971; 310:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/27\">",
"      Rudge P, Webster AD, Revesz T, et al. Encephalomyelitis in primary hypogammaglobulinaemia. Brain 1996; 119 ( Pt 1):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/28\">",
"      Lau YL, Levinsky RJ, Morgan G, Strobel S. Dual meningoencephalitis with echovirus type 11 and adenovirus in combined (common variable) immunodeficiency. Pediatr Infect Dis J 1988; 7:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/29\">",
"      Ziegner UH, Kobayashi RH, Cunningham-Rundles C, et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol 2002; 102:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/30\">",
"      Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999; 104:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/31\">",
"      Cadranel J, Bouvry D, Wislez M. [Respiratory manifestations of common variable immunodeficiency in adults]. Rev Mal Respir 2003; 20:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/32\">",
"      Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/33\">",
"      Agondi RC, Barros MT, Rizzo LV, et al. Allergic asthma in patients with common variable immunodeficiency. Allergy 2010; 65:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/34\">",
"      Bates CA, Ellison MC, Lynch DA, et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004; 114:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/35\">",
"      Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol 2010; 134:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/36\">",
"      Park JE, Beal I, Dilworth JP, et al. The HRCT appearances of granulomatous pulmonary disease in common variable immune deficiency. Eur J Radiol 2005; 54:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/37\">",
"      Thickett KM, Kumararatne DS, Banerjee AK, et al. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM 2002; 95:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/38\">",
"      Aghamohammadi A, Allahverdi A, Abolhassani H, et al. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia. Respirology 2010; 15:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/39\">",
"      Wheat WH, Cool CD, Morimoto Y, et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med 2005; 202:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/40\">",
"      Zullo A, Romiti A, Rinaldi V, et al. Gastric pathology in patients with common variable immunodeficiency. Gut 1999; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/41\">",
"      Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009; 124:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/42\">",
"      Guo BC, Saxon A. B cell lines from a subset of patients with common variable immunodeficiency undergo enhanced apoptosis associated with an increased display of CD95 (Apo-1/fas), diminished CD38 expression, and decreased IgG and IgA production. Cell Immunol 1995; 166:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/43\">",
"      Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep 2004; 6:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/44\">",
"      Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol 2007; 31:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/45\">",
"      Detkov&aacute; D, de Gracia J, Lopes-da-Silva S, et al. Common variable immunodeficiency: association between memory B cells and lung diseases. Chest 2007; 131:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/46\">",
"      Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/47\">",
"      Boileau J, Mouillot G, G&eacute;rard L, et al. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun 2011; 36:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/48\">",
"      Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008; 28 Suppl 1:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/49\">",
"      Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009; 9:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/50\">",
"      Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004; 83:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/51\">",
"      S&egrave;ve P, Bourdillon L, Sarrot-Reynauld F, et al. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. Medicine (Baltimore) 2008; 87:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/52\">",
"      Giannouli S, Anagnostou D, Soliotis F, Voulgarelis M. Autoimmune manifestations in common variable immunodeficiency. Clin Rheumatol 2004; 23:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/53\">",
"      Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/54\">",
"      Sarmiento E, Mora R, Rodr&iacute;guez-Mahou M, et al. [Autoimmune disease in primary antibody deficiencies]. Allergol Immunopathol (Madr) 2005; 33:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/55\">",
"      Arunachalam M, Sanzo M, Lotti T, et al. Common variable immunodeficiency in vitiligo. G Ital Dermatol Venereol 2010; 145:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/56\">",
"      Fern&aacute;ndez-Castro M, Mellor-Pita S, Citores MJ, et al. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum 2007; 36:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/57\">",
"      Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997; 127:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/58\">",
"      Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol 2009; 133:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/59\">",
"      Artac H, Bozkurt B, Talim B, Reisli I. Sarcoid-like granulomas in common variable immunodeficiency. Rheumatol Int 2009; 30:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/60\">",
"      Boursiquot JN, G&eacute;rard L, Malphettes M, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol 2013; 33:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/61\">",
"      Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/62\">",
"      Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore) 1996; 75:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/63\">",
"      Kanathur N, Byrd RP Jr, Fields CL, Roy TM. Noncaseating granulomatous disease in common variable immunodeficiency. South Med J 2000; 93:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/64\">",
"      Arnold DF, Wiggins J, Cunningham-Rundles C, et al. Granulomatous disease: distinguishing primary antibody disease from sarcoidosis. Clin Immunol 2008; 128:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/65\">",
"      Marashi SM, Raeiszadeh M, Workman S, et al. Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus. J Allergy Clin Immunol 2011; 127:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/66\">",
"      Ward C, Lucas M, Piris J, et al. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol 2008; 153:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/67\">",
"      Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol 2008; 48:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/68\">",
"      Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002; 130:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/69\">",
"      Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol 1987; 7:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/70\">",
"      Aghamohammadi A, Rezaei N, Gharagozlou M, et al. Hodgkin lymphoma in two siblings with common variable immunodeficiency. Pediatr Hematol Oncol 2007; 24:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/71\">",
"      Vorechovsk&yacute; I, Cullen M, Carrington M, et al. Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol 2000; 164:4408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/72\">",
"      Dhalla F, da Silva SP, Lucas M, et al. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol 2011; 165:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/73\">",
"      Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/74\">",
"      Orange JS, Glessner JT, Resnick E, et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol 2011; 127:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/75\">",
"      International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009; 124:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/76\">",
"      Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/77\">",
"      Hunter ZR, Manning RJ, Hanzis C, et al. IgA and IgG hypogammaglobulinemia in Waldenstr&ouml;m's macroglobulinemia. Haematologica 2010; 95:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/28/17866/abstract/78\">",
"      Kelesidis T, Yang O. Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence. Clin Immunol 2010; 135:347.",
"     </a>",
"    </li>",
"    <li>",
"     Patient information about specific disorders is available at: file://primaryimmune.org/about-primary-immunodeficiency-diseases/types-of-pidd (Accessed on January 19, 2012).",
"    </li>",
"    <li>",
"     Patient information about specific immunodeficiencies can be found at: file://www.info4pi.org/aboutPI/index.cfm?section=aboutPI&amp;content=defects (Accessed on January 19, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3928 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17866=[""].join("\n");
var outline_f17_28_17866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191858\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191865\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193444\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193458\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25083002\">",
"      - Most common pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25083082\">",
"      Other pathogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25083016\">",
"      - Sinopulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25083192\">",
"      - Gastrointestinal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25083250\">",
"      - Other infectious disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193479\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8458064\">",
"      - Types of lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9597804\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193493\">",
"      Autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193500\">",
"      Granulomatous infiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193507\">",
"      Allergic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193514\">",
"      Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193521\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193528\">",
"      Malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1193535\">",
"      - Non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1193542\">",
"      - Gastric cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193549\">",
"      Neurologic degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1196168\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2193210\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2193234\">",
"      Indications for referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1196176\">",
"      Routine laboratories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunoglobulin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vaccine response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Variable laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Molecular analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19776367\">",
"      Secondary hypogammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19776374\">",
"      - Decreased production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19776381\">",
"      - Increased loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary hypogammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14472870\">",
"      - IgG subclass deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14472930\">",
"      - Hyper IgM syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14473235\">",
"      - Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3928\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3928|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/4/33870\" title=\"picture 1\">",
"      Lymphoid hyperplasia TI Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3928|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/38/1644\" title=\"table 1\">",
"      Autoimmunity in CVID",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21001?source=related_link\">",
"      Hyperimmunoglobulin M syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37095?source=related_link\">",
"      Nodular regenerative hyperplasia of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=related_link\">",
"      Treatment and prognosis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_28_17867="Echinococcosis serologic tests";
var content_f17_28_17867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity of serologic tests for echinococcosis at different sites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site of lesion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity of serologic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Liver",
"       </td>",
"       <td>",
"        IgG ELISA: 80-90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgE ELISA: 82-92 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latex agglutination: 65-75 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemagglutination: 80-90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunoblot (using antigen 5 and/or a B-rich fraction): 80-90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enzyme-linked immunotransfer blot: 80 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Lung",
"       </td>",
"       <td>",
"        IgG ELISA: 60-85 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgE ELISA: 45-70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latex agglutination: 50-70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemagglutination: 50-70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunoblot (using antigen 5 and/or a B-rich fraction): 55-70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enzyme-linked immunotransfer blot: 55 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17867=[""].join("\n");
var outline_f17_28_17867=null;
var title_f17_28_17868="Triage scoring systems";
var content_f17_28_17868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of prehospital triage scoring systems",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellpadding=\"0\" cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Name",
"      </td>",
"      <td class=\"subtitle1_single\">",
"       Parameters",
"      </td>",
"      <td class=\"subtitle1_single\">",
"       Notes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prehospital Index",
"      </td>",
"      <td>",
"       <p>",
"        Systolic BP",
"       </p>",
"       <p>",
"        Pulse rate",
"       </p>",
"       <p>",
"        Respiratory rate",
"       </p>",
"       <p>",
"        Consciousness",
"       </p>",
"       <p>",
"        Penetrating wounds (chest or abdomen)",
"       </p>",
"      </td>",
"      <td>",
"       Scale is 0 to 24 (&gt;3: major trauma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CRAMS (Circulation, Respiration, Abdomen/Thorax, Motor, Speech)",
"      </td>",
"      <td>",
"       <p>",
"        Systolic BP or capillary refill",
"       </p>",
"       <p>",
"        Respirations",
"       </p>",
"       <p>",
"        Examination of trunk",
"       </p>",
"       <p>",
"        Motor function",
"       </p>",
"       <p>",
"        Speech pattern",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Scale is 0 to 10 (&lt;8: major trauma)",
"       </p>",
"       <p>",
"        Each parameter rated as normal, mildly abnormal, or highly abnormal",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Revised Trauma Score",
"      </td>",
"      <td>",
"       <p>",
"        Systolic BP",
"       </p>",
"       <p>",
"        Respiratory rate",
"       </p>",
"       <p>",
"        GCS",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0 to 7.8408 (&lt;4: major trauma)",
"       </p>",
"       <p>",
"        GCS more heavily weighted",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       START (Simple triage and rapid treatment)",
"      </td>",
"      <td>",
"       <p>",
"        Ambulation",
"       </p>",
"       <p>",
"        Respiratory rate",
"       </p>",
"       <p>",
"        Capillary refill",
"       </p>",
"       <p>",
"        Consciousness",
"       </p>",
"      </td>",
"      <td>",
"       Stepwise algorithm designed for ease of use in mass casualty incident",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       GCS (Glasgow Coma Scale)",
"      </td>",
"      <td>",
"       <p>",
"        Eye response",
"       </p>",
"       <p>",
"        Verbal response",
"       </p>",
"       <p>",
"        Motor response",
"       </p>",
"      </td>",
"      <td>",
"       Scale is 3 to 15 (&lt;8: severe brain injury)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MGAP (Mechanism, GCS, Age, arterial Pressure)",
"      </td>",
"      <td>",
"       <p>",
"        Mechanism (blunt)",
"       </p>",
"       <p>",
"        GCS",
"       </p>",
"       <p>",
"        Age (60 years)",
"       </p>",
"       <p>",
"        Systolic BP",
"       </p>",
"      </td>",
"      <td>",
"       Scale is 3 to 29 (&lt;18: high risk)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17868=[""].join("\n");
var outline_f17_28_17868=null;
var title_f17_28_17869="Diaphragmatic fatigue";
var content_f17_28_17869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recovery from diaphragmatic fatigue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 277px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Induction of diaphragmatic fatigue (red bar) produced a significant fall in transdiaphragmatic twitch pressure (Pditw). Nadir of Pditw was reached 10 minutes after conclusion of fatigue protocol, and PDitw values at 8 and 24 hours remained lower than baseline (BL). Significant difference compared with BL value, p &lt; 0.01.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Laghi, F, D'Alfonso, N, Tobin, MJ, J Appl Physiol 1995; 79:539",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17869=[""].join("\n");
var outline_f17_28_17869=null;
var title_f17_28_17870="Combination Rx and proteinuria";
var content_f17_28_17870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Superior antiproteinuric effect with combination antihypertensive therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 280px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in protein excretion over a one-year period in patients with type 2 diabetes mellitus randomly assigned to verapamil SR, trandolapril, or combination. Protein excretion was significantly less at nine and 12 months in the combination therapy group, as compared with either of the single-drug groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bakris GL, Weir MR, DeQuattro V, et al. Kidney Int 1998; 54:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17870=[""].join("\n");
var outline_f17_28_17870=null;
var title_f17_28_17871="B cell dev in germ centers";
var content_f17_28_17871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    B cell development in the germinal center",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 460px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One or a few B cell clones colonize the forming germinal center. These clones have been activated elsewhere and are retained via interaction with antigen present in immune complexes (Ag-IC) on the surface of follicular dendritic cells (FDC). They undergo proliferation with class-switching and Ig V gene somatic hypermutation. If mutation destroys antigen-binding, the cell dies because it cannot interact with FDC's in the basal light zone. High-affinity cells migrate to the apical light zone where, depending on particular cellular signals and/or cytokines provided by T cells, they differentiate either into memory cells or plasma cells. It is possible that some cells may also return to the dark zone for further cycles of division and mutation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Bona, C, Bonilla, F. B Cells and Humoral Immunity. In: Textbook of Immunology, second edition, Harwood Academic Publishers 1996. Page 128, figure 5-16. Original source: Liu et al. Germinal centers in T-cell dependant antibody responses. Immunology Today 1992; 13:17-21. figure 2.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_28_17871=[""].join("\n");
var outline_f17_28_17871=null;
